



OTHER RELEVANT INFORMATION

PLÁSTICOS COMPUESTOS, S.A.

22 May 2026

Pursuant to the provisions of Article 17 of Regulation (EU) No 596/2014 on Market Abuse and Article 227 of Law 6/2023 of 17 March on Securities Markets and Investment Services, and related provisions, as well as Circular 3/2020 of 30 July 2020 on information to be provided by companies listed on BME Growth, Plásticos Compuestos, S.A. (the “Company”) hereby provides the following information:

In accordance with the provisions of Article 172 of the Companies Act, and in response to the request from shareholders holding 1,227,899 shares representing 9.10% of the share capital, notified to the Company on 18 May 2026, the Board of Directors of the Company hereby publishes the following supplementary notice of the ordinary general meeting of shareholders, to be held on 17 June 2026 at Carrer Basters 15, Palau Solità i Plegamans (Barcelona), at 12:00 noon, on first call, and, should the necessary quorum not be present, on 18 June 2026, at the same place and time, on second call.

In view of the above, the notice of the meeting published on 15 May 2026 on the BME Growth website is hereby supplemented, incorporating two new items on the agenda as items 19 and 20, in addition to those appearing in the notice of the general meeting, with the following wording, a verbatim transcription of the request for supplementation received at the registered office:

1. *“Consideration and, where appropriate, approval of instructions to the Board of Directors, in accordance with Article 161 of the Companies Act, regarding the suitability and composition of the Board following the previously approved resignations/appointments. In particular, it is proposed (i) to require the Appointments and Remuneration Committee to issue, within a maximum period of 30 days, an ex post suitability report on the appointed directors and on the adequacy and balance of the Board’s current composition (categories, independence and diversity), (ii) to establish a strict abstention regime for members of the Nomination and Remuneration Committee and the Board of Directors who are subject to a conflict of interest or have relevant links in this regard, (iii) provide that, should the Committee be unable to issue the opinion with guarantees of impartiality or a quorum, such analysis shall be delegated to an independent external expert appointed by the Board, (iv) require the Board to adopt the appropriate decisions in light of the opinion, and (v) inform the General Meeting, and the market where required, of the outcome and the measures adopted.”*
2. *“Review and, where appropriate, approval of instructions to the Board of Directors regarding related-party transactions, pursuant to Article 161 of the Companies Act, with the following content: (i) participation of independent directors in the drafting of the Related-Party Transactions Protocol commissioned from KPMG, with a strict abstention regime for members involved in a conflict of interest, (ii) creation of a comprehensive and accessible document repository to ensure traceability and transparency, including complete master file reports, and (iii) submission of an annual report to the General Meeting on the implementation, compliance and effectiveness of the measures adopted.”*

As a result of the inclusion of these two new items on the agenda of the aforementioned ordinary general meeting of shareholders, the new agenda is as follows:

AGENDA

1. Confirmation of the valid constitution of the ordinary general meeting of shareholders, the agenda and the appointments of the chair and secretary.
2. Examination and approval, where applicable, of the annual accounts and the management report for the financial year ended 31 December 2025.
3. Approval of the proposed appropriation of profits for the financial year ended 31 December 2025.
4. Review and approval of the management and conduct of the Board of Directors and its Audit Committee during the 2025 financial year.
5. Removal of the members of the Company's Board of Directors.
6. Appointment of a member of the Company's Board of Directors.
7. Appointment of a member of the Company's Board of Directors.
8. Appointment of a member of the Company's Board of Directors.
9. Appointment of a member of the Company's Board of Directors.
10. Appointment of a member of the Company's Board of Directors.
11. Appointment of a member of the Company's Board of Directors.
12. Appointment of a member of the Company's Board of Directors.
13. Appointment of a member of the Company's Board of Directors.
14. Confirmation of the appointment of Mr Josep Maria Torner Ribe as an independent director by co-optation.
15. Approval of the remuneration of the members of the Board of Directors for the 2027 financial year.
16. Authorisation for the Board of Directors, in accordance with the provisions of Article 297.1.b) of the Companies Act, to increase the share capital on one or more occasions and at any time, within a period of 5 years, through cash contributions and up to a maximum nominal amount of €4,049,670.30. Delegation of powers to exclude pre-emptive subscription rights, in accordance with the provisions of Article 506 of the Companies Act. Revocation of the aforementioned authorisations.
17. Authorisation for the Board of Directors to issue securities convertible into shares of the Company within a period of 5 years. Establishment of criteria for determining the terms and conditions of conversion and conferral of

powers to increase capital. Delegation to exclude pre-emptive subscription rights, in accordance with the provisions of Article 506 of the Capital Companies Act. Revocation of previous authorisations.

18. Authorisation for the Company to acquire its own shares indirectly. Revocation of previous authorisations.
19. Review and, where appropriate, approval of instructions to the Board of Directors, in accordance with Article 161 of the Companies Act, regarding the suitability and composition of the Board following the previously approved resignations/appointments. In particular, it is proposed (i) to require the Appointments and Remuneration Committee to issue, within a maximum period of 30 days, an ex post suitability report on the appointed directors and on the adequacy and balance of the Board's current composition (categories, independence and diversity), (ii) to establish a strict abstention regime for members of the Nomination and Remuneration Committee and the Board of Directors who are subject to a conflict of interest or have relevant links in this regard, (iii) provide that, should the Committee be unable to issue the opinion with guarantees of impartiality or a quorum, such analysis shall be delegated to an independent external expert appointed by the Board, (iv) require the Board to adopt the appropriate decisions in light of the opinion, and (v) inform the General Meeting, and the market where required, of the outcome and the measures adopted.
20. Review and, where appropriate, approval of instructions to the Board of Directors regarding related-party transactions, pursuant to Article 161 of the Companies Act, with the following content: (i) the involvement of independent directors in the drafting of the Related-Party Transactions Protocol commissioned from KPMG, with a strict abstention policy for members subject to a conflict of interest, (ii) creation of a comprehensive and accessible document repository to ensure traceability and transparency, including complete master file reports, and (iii) submission of an annual report to the General Meeting on the implementation, compliance and effectiveness of the measures adopted.
21. Delegation of powers.
22. Questions and comments.
23. Drafting, reading and, where applicable, approval of the minutes.

In compliance with the provisions of Circular 3/2020 of the BME Growth segment of BME MTF Equity, it is hereby expressly stated that the information communicated herein has been prepared under the sole responsibility of the Company and its directors.

This document is signed by the Chairman of the Company's Board of Directors, Corporation Chimique International S.P.R.L., duly represented by Mr Ignacio Duch Tuesta, by virtue of the delegation of powers conferred for this purpose by the Board of Directors itself at its meeting held on 14 May 2026.

We remain at your disposal for any clarifications you may require.

At Palau-Solità i Plegamans (Barcelona), on 22 May 2026.

Corporation Chimique International S.P.R.L.
On behalf of Mr Ignacio Duch Tuesta
Chairman of the Board of Directors